文献速递脑血管病

因子XIa抑制剂用于非心源性栓塞性卒中二级预防:系统综述与荟萃分析

Factor XIa Inhibitors for Secondary Prevention After Noncardioembolic Stroke: A Systematic Review and Meta-Analysis.
PubMed 文献 · Neurology · 2026-09-16

该系统综述与荟萃分析纳入3项随机对照试验共14,239例急性非心源性栓塞性缺血性卒中或TIA患者,比较因子XIa抑制剂与安慰剂。结果显示FXIa抑制剂降低任何卒中、缺血性卒中及复合心血管事件风险,且未增加大出血、出血性卒中、颅内出血、任何出血或全因死亡风险。

要点

  • FXIa抑制剂降低任何卒中风险(RR=0.75;95%CI 0.66-0.84)。
  • FXIa抑制剂未增加大出血风险(RR=1.12;95%CI 0.87-1.44)。
  • 效应估计主要来自一项纳入12,327例的3期试验。

核心结论

  • 在急性非心源性栓塞性缺血性卒中或TIA后,标准抗血小板治疗基础上加用FXIa抑制剂可降低卒中复发风险,且无出血风险增加的证据。

研究设计与样本

  • 系统检索MEDLINE和Scopus,纳入比较FXIa抑制剂与安慰剂的随机对照试验,共3项RCT、14,239例参与者(FXIa抑制剂组6,927例,安慰剂组7,312例)。

主要发现

  • FXIa抑制剂降低任何卒中风险(RR=0.75;95%CI 0.66-0.84)。
  • FXIa抑制剂降低缺血性卒中风险(RR=0.74;95%CI 0.66-0.84)。
  • FXIa抑制剂降低复合心血管事件风险(RR=0.83;95%CI 0.75-0.92)。
  • FXIa抑制剂未增加大出血风险(RR=1.12;95%CI 0.87-1.44)。
  • FXIa抑制剂未增加出血性卒中、颅内出血、任何出血或全因死亡风险。

关键数值与推荐

  • 主要疗效结局为首次卒中(缺血性、出血性或未明确),主要安全结局为随访期间首次大出血事件。
  • 效应估计主要来自一项纳入12,327例参与者的3期试验。

临床怎么用

  • 对于急性非心源性栓塞性缺血性卒中或TIA患者,可考虑在标准抗血小板治疗基础上加用FXIa抑制剂以降低卒中复发风险。

局限性

  • 仅纳入3项RCT,且效应估计主要驱动于单一3期试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Patients with noncardioembolic ischemic stroke or transient ischemic attack (TIA) remain at substantial risk of recurrent ischemic events, despite guideline-recommended antithrombotic therapy. Factor XIa (FXIa) inhibitors may reduce thrombotic risk while preserving hemostasis. METHODS: We systematically searched MEDLINE and Scopus for randomized-controlled clinical trials (RCTs) comparing FXIa inhibitors with placebo in patients with acute noncardioembolic ischemic stroke or TIA. Primary efficacy outcome was first stroke (ischemic, hemorrhagic, or undefined), and primary safety outcome was first major bleeding event during follow-up. Risk ratios (RRs) with 95% CIs were pooled using random-effects models. RESULTS: Three RCTs recruiting 14,239 participants (6,927 assigned to FXIa inhibitors and 7,312 to placebo) were included. Effect estimates were largely driven by a single phase 3 trial, recruiting 12,327 participants. FXIa inhibitors reduced the risks for any stroke (RR = 0.75; 95% CI 0.66-0.84), ischemic stroke (RR = 0.74; 95% CI 0.66-0.84), and composite cardiovascular events (RR = 0.83; 95% CI 0.75-0.92), when compared with placebo. FXIa inhibitors did not increase the risks for major bleeding (RR = 1.12; 95% CI 0.87-1.44), hemorrhagic stroke, intracranial hemorrhage, any bleeding, or all-cause mortality. DISCUSSION: The addition of a FXIa inhibitor to standard antiplatelet therapy after an acute noncardioembolic ischemic stroke or TIA reduces the risk of stroke recurrence without evidence of an increased bleeding risk.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Katsanos AH, Shoamanesh A, Palaiodimou L, et al. Factor XIa Inhibitors for Secondary Prevention After Noncardioembolic Stroke: A Systematic Review and Meta-Analysis. Neurology. 2026. PMID: 42748394. doi:10.1212/WNL.0000000000218521

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。